CN-122005465-A - MOFs drug carrier material rapidly coated by polydopamine and preparation method and application thereof

CN122005465ACN 122005465 ACN122005465 ACN 122005465ACN-122005465-A

Abstract

The invention belongs to the technical field of biomedical materials, and relates to a polydopamine fast-coated MOFs drug carrier material, a preparation method and application thereof. In the polydopamine fast-coated MOFs drug carrier material, partially polymerized polydopamine PDA is fast coated on the surface of the MOFs nano-porous material, and the required drugs are loaded in the inner pore canal of the MOFs nano-porous material. The invention utilizes the adhesion effect of catechol in polydopamine to make the catechol in-situ polymerized on the surface of MOFs particles loaded by anti-inflammatory drugs, has good photo-thermal conversion and drug slow release performance, reduces the difficulty of premature release of drugs in the carrier caused by long-time modification process of PDA, endows the drug carrier with excellent photo-thermal conversion and drug slow release capability, and enhances the therapeutic effect of the drug carrier on OA.

Inventors

LIU JIANXI
Tian Lejie
WANG LONG
XU YADONG
LIU WEIMIN

Assignees

西北工业大学

Dates

Publication Date: 20260512
Application Date: 20260127

Claims (10)

1. A polydopamine fast-coated MOFs drug carrier material is characterized in that in the polydopamine fast-coated MOFs drug carrier material, partially polymerized polydopamine PDA is fast coated on the surface of a MOFs nano-porous material, and required drugs are loaded in an inner pore canal of the MOFs nano-porous material.
2. The rapidly coated MOFs drug carrier material of claim 1 wherein the polydopamine rapidly coats the surface of the MOFs nano-porous material by in-situ polymerization.
3. The rapidly coated MOFs drug carrier material of polydopamine of claim 1 wherein the drug is an anti-inflammatory drug for treating osteoarthritis and the anti-inflammatory drug is a non-steroidal anti-inflammatory drug.
4. A method for preparing the polydopamine fast-coated MOFs drug carrier material according to claim 1,2 or 3, which is characterized by comprising the following steps: Step 1, synthesizing MOFs nano-porous material Taking metal ion salt and an organic ligand as raw materials, reacting by a microwave method or a solvothermal method, and then separating, washing and drying to obtain the MOFs nano-porous material; Step 2, preparing the MOFs nano-porous material carrying the medicine Dispersing the MOFs nano-porous material obtained in the step 1 in water, then adding the required medicine, fully mixing and stirring through ultrasonic dispersion, and then centrifuging, washing and drying to obtain the medicine-carrying MOFs nano-porous material; Step 3 preparation of partially polymerized Polydopamine solution Dispersing dopamine monomers in Tris buffer solution, and stirring and polymerizing in a dark place to obtain partially polymerized polydopamine solution; step 4, preparing MOFs drug carrier material coated by polydopamine rapidly And (3) adding the drug-loaded MOFs nano-porous material in the step (2) into the partially polymerized polydopamine solution in the step (3), and stirring in a dark place to perform in-situ polymerization reaction to obtain the MOFs drug carrier material rapidly coated by polydopamine.
5. The method according to claim 4, wherein in the step 1, the ionic salt is hydrated cadmium nitrate or cadmium nitrate, the organic ligand is phthalic acid, biphenyl dicarboxylic acid, 2-amino terephthalic acid, 2-amino biphenyl dicarboxylic acid or 2,2 '-bipyridine-4, 4' -dicarboxylic acid, and the molar ratio of the metal ionic salt to the organic ligand is (1-300): (1-200).
6. The method of claim 5, wherein the reaction temperature is 60-200 ℃ and the reaction time is 2 h-12 h.
7. The preparation method of the dopamine-containing polymer, as set forth in claim 4, characterized in that the specific step of the step 3 is to disperse dopamine monomers in Tris buffer, keep the temperature at 25-35 ℃ at pH=7-9, and stir the solution for 0.5-1.5 h away from light to polymerize the solution to obtain the partially polymerized polydopamine solution.
8. The method of claim 4, wherein in step 4, the in-situ polymerization reaction is carried out at a temperature of 25-35 ℃ by stirring in the absence of light, and the reaction is 0.5 h-2 h.
9. Application of polydopamine fast coated MOFs drug carrier material in preparing OA therapeutic drug carrier additive.
10. An OA therapeutic drug carrier having excellent photothermal conversion property and drug release property, characterized by being obtained by dissolving the polydopamine fast-coated MOFs drug carrier material according to claim 1 in a solvent.

Description

MOFs drug carrier material rapidly coated by polydopamine and preparation method and application thereof Technical Field The invention belongs to the technical field of biomedical materials, and relates to a polydopamine fast-coated MOFs drug carrier material, a preparation method and application thereof. Background Osteoarthritis (Osteoarthritis, OA) is a chronic disease characterized by gradual degeneration of joint structures, and is very common in clinic, and its typical pathological changes involve destruction of articular cartilage, thickening of synovial tissue, abnormal deposition of calcium salt in the joint cavity, narrowing of joint space, formation of osteophytes, etc. Osteoarthritis poses a threat to the health of people, especially the elderly. Therefore, improvement of preventive treatment strategies is an important direction of current medical research. The clinical treatment method of osteoarthritis mainly focuses on two modes of surgical treatment and drug treatment. The treatment of both methods is specifically as follows: The surgical treatment often adopts two schemes of a microfracture surgical scheme, i.e., a scheme of alleviating a small-scale joint defect and restoring function by locally generating fibrocartilage from bone marrow, but such a method is generally unsuitable for providing a long-term alleviating effect due to low abrasion resistance of the fibrocartilage, or for the occurrence of a large-scale defect. Clinical strategies for joint replacement include autologous osteochondral grafting and allograft grafting, which, while well solving the problem of osteoarthritis disease, can create a serious economic burden for the patient due to excessive costs and the possible need for secondary surgery. Drug therapy is commonly used in the early treatment of osteoarthritis. Drug therapy is mainly focused on pain and inflammation relief by oral or intra-articular injection and the like. However, oral administration does not control the rate of drug release, is prone to overdose due to too fast drug absorption or excessive drug metabolism, reduces the therapeutic effect of the drug, and may lead to many possible gastrointestinal, cardiovascular or other complications. Intra-articular injection of hyaluronic acid can alleviate pain of patients and improve the problem of insufficient lubrication, but there is a shear thinning phenomenon, the lubrication effect gradually declines, and multiple injections are required. In view of the defects of surgical treatment and drug treatment, a non-surgical intervention technology is developed, has dual functions of enhancing joint lubrication and realizing local slow release drug delivery, and has important clinical significance for delaying cartilage abrasion and controlling inflammatory process. Phototherapy (Photothermal Therapy, PTT) has attracted considerable interest to researchers in inhibiting tumors, eliminating inflammation, and slowing down OA processes due to the non-invasive and space-time selectivity advantages, effectively converting Near Infrared (NIR) light energy into thermal energy by using photothermal conversion agents. Many photothermal materials, such as gold nanoparticles, polydopamine, molybdenum disulfide, and carbon dots, have been successfully used as photothermal conversion agents. Among these phototherapeutic agents, polydopamine (PDA) is a promising nanomaterial, which is simple in preparation process, high in light-heat conversion efficiency, particularly has surprising adhesive properties, and can be free from the limitation of substrates. Dopamine can be modified on a substrate matrix through mild autoxidation polymerization under alkaline conditions to form a polydopamine structure, so that the biocompatibility, dispersion stability, adhesive strength and surface re-modification activity of the nano material are realized. However, conventional modification of the PDA nanolayer on the surface of the substrate typically requires 12-24 h. Long modification often results in premature release of the drug in the carrier, further diminishing the therapeutic effect of the drug carrier on Osteoarthritis (OA). Disclosure of Invention Aiming at the technical problems that the conventional modification process of the PDA nano layer on the surface of the substrate generally needs 12 h-24 h, and the long-time modification process generally causes premature release of the drug in the carrier, and further weakens the effect of the drug carrier on Osteoarthritis (OA), the invention provides a polydopamine rapidly-coated MOFs drug carrier material, and a preparation method and application thereof. The conception of the invention is as follows: The MOFs nano porous material is used as an osteoarthritis drug delivery carrier, is combined with a partially polymerized polydopamine layer, and is polymerized on the surface of MOFs particles loaded by anti-inflammatory drugs in situ by utilizing the adhesion effect of catechol in polydo